Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular Atrophy (SMA) Patients.
Sponsor: Association Française contre les Myopathies (AFM), Paris
This PHASE2 trial investigates Spinal Muscular Atrophy Type II and Spinal Muscular Atrophy Type III Non Ambulant and is currently completed. Association Française contre les Myopathies (AFM), Paris leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Association Française contre les Myopathies (AFM), Paris
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birmingham, United Kingdom , Bron, France , Essen, Germany , Freiburg im Breisgau, Germany , Garches, France , Genova, Italy , Ghent, Belgium , Leuven, Belgium , Lille, France , London, United Kingdom and 10 more locations